دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Elacestrant: who are optimal candidates for the first oral SERD?
M. Lipsyc-Sharf 1,2,3 & S. M. Tolaney
doi : 10.1016/j.annonc.2023.02.006
Volume 34, Issue 5, May 2023, Pages 449-451
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline☆
A. Falanga1,2 , C. Ay 3 , M. Di Nisio 4 , G. Gerotziafas5 , L. Jara-Palomares 6,7 , F. Langer 8 , R. Lecumberri 9,10 , M. Mandala 11 , A. Maraveyas 12 , I. Pabinger3 , M. Sinn 8 , K. Syrigos13 , A. Young14 & K. Jordan 15,16 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.12.014
Volume 34, Issue 5, May 2023, Pages 452-467
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
J. Remon 1 , B. Besse 1 , S. Ponce Aix2 , A. Callejo 3 , K. Al-Rabi 4 , R. Bernabe5 , L. Greillier 6 , M. Majem 7 , N. Reguart 8 , I. Monnet 9 , S. Cousin 10 , P. Garrido 11 , G. Robinet 12 , R. Garcia Campelo13 , A. Madroszyk14 , J. Mazières 15 , H. Curcio 16 , B. Wasąg 17 , Y. Pretzenbacher 18 , B. Fournier 18 , A.-M. C. Dingemans19 & R. Dziadziuszko 17*
doi : 10.1016/j.annonc.2023.02.012
Volume 34, Issue 5, May 2023, Pages 468-476
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer☆
S. Chowdhury 1,2* , A. Bjartell 3 , N. Agarwal 4 , B. H. Chung 5 , R. W. Given6 , A. J. Pereira de Santana Gomes7 , A. S. Merseburger8 , M. Özgüroglu9 , �. Juárez Soto 10 , H. Uemura11 , D. Ye 12 , S. D. Brookman-May13,14 , A. Londhe 15 , A. Bhaumik 15 , S. D. Mundle16 , J. S. Larsen17 , S. A. McCarthy16 & K. N. Chi
doi : 10.1016/j.annonc.2023.02.009
Volume 34, Issue 5, May 2023, Pages 477-485
Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies☆
Q. Gao1,2y, Y. P. Lin 1,2y, B. S. Li3y, G. Q. Wang 3y, L. Q. Dong1,2 , B. Y. Shen4 , W. H. Lou5 , W. C. Wu5 , D. Ge6 , Q. L. Zhu6 , Y. Xu3 , J. M. Xu5 , W. J. Chang5 , P. Lan7 , P. H. Zhou8 , M. J. He8 , G. B. Qiao9 , S. K. Chuai3 , R. Y. Zang10 , T. Y. Shi10 , L. J. Tan6 , J. Yin6 , Q. Zeng11 , X. F. Su12 , Z. D. Wang13 , X. Q. Zhao14 , W. Q. Nian15 , S. Zhang1 , J. Zhou1,2 , S. L. Cai3 , Z. H. Zhang3 & J. Fan
doi : 10.1016/j.annonc.2023.02.010
Volume 34, Issue 5, May 2023, Pages 486-495
A simple way of doing the complex but utmost important things: cancer pain management
S. Singhal 1 , M. Verma 2 * & D. Kukreja
doi : 10.1016/j.annonc.2023.02.002
Volume 34, Issue 5, May 2023, Page 496
Reply to the Letter to the Editor “A simple way of doing the complex but utmost important things: cancer pain management� by S. Singhal, M. Verma and D. Kukreja
M. T. Fallon1 *, A. Caraceni 2 , B. J. A. Laird1 & S. Kaasa
doi : 10.1016/j.annonc.2023.02.005
Volume 34, Issue 5, May 2023, Pages 496-497
Bureaucracy or streamlining the rules in ‘Good Clinical Practice (GCP)’—has equipoise occurred?
H. K. Kotakonda*, V. G. Jonnalagadda & S. R. Venna
doi : 10.1016/j.annonc.2023.01.013
Volume 34, Issue 5, May 2023, Pages 497-498
Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)� - Has Equipoise Occurred?� by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna
J. L. Perez-Gracia 1 *, N. Penel2,3 , E. Calvo4 , H. T. Arkenau 5 , T. Amaral6,7 , V. Grünwald 8 & M. F. Sanmamed
doi : 10.1016/j.annonc.2023.02.003
Volume 34, Issue 5, May 2023, Pages 498-499
VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
M. R. Mirza1, D. Chase 2 , B. M. Slomovitz 3 , R. D. Christensen 4 , Z. Novák 5 , D. Black 6 , L. Gilbert 7 , S. Sharma8 , G. Valabrega 9 , L. M. Landrum 10 , L. C. Hanker 11 , A. Stuckey 12 , I. A. Boere 13 , M. Gold 14 , S. E. Gill 15 , B. J. Monk 16 , Z. He 17 , S. Stevens 18 , R. L. Coleman19 & M. A. Powell
doi : 10.1016/j.annonc.2023.02.008
Volume 34, Issue 5, May 2023, Pages 500-501
Corrigendum to “1773P Prediction of chemotherapy response in muscle-invasive bladder cancer: A machine learning approach�: [Annals of Oncology 32 (2022) S1348]
E. Shkolyar 1* , H. Bhambhvani 2 , E. Tiu2 , V. Krishna 2 , V. Krishna 2 , V. Nimgaonkar 2 , R. Krishnan 2 , O. O’Donoghue2 , D. Vrabac 2 , C-S. Kao 3 , A. Joshi 2 & J. Shah
doi : 10.1016/j.annonc.2023.02.014
Volume 34, Issue 5, May 2023, Page 502
